Despite giant leaps in the field of medicine that have resulted in better outcomes for patients, several new treatment procedures are still considered 'unproven' by health insurance companies. Until 2019, many general and health insurance companies were reluctant to pay for advanced treatment procedures such as stem cell therapy, robotic surgery, oral chemotherapy, and so on.
Valuations in Indian markets have become reasonable: Mirae's CIO Surana
Read More